Sandoz International GMBH engaged in "multiple repeated violations" of current good manufacturing practices, while parent company Novartis AG "is not implementing global and sustainable corrective actions," according to an FDA warning letter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?